U.S. FDA approves Glaxo, Theravance's Breo Ellipta asthma drug
April 30, 2015 at 17:31 PM EDT
April 30 (Reuters) - The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said.
